Oxford Biomedica Ltd.
| London Stock Exchange: OXB
Oxford Biomedica Ltd. operates as a biopharmaceutical company. It develops innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The company's technology platform includes LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen 5T4, which is an ideal target for anti-cancer therapy. Its products include Prosavin, Retinostat, Stargen, Ushstat, Encorstat, Monudin, Trovax, Glaucoma-GT and Anti-5T4 antibody. Oxford Biomedica was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.